Investigation of the safety and efficacy of human growth hormone replacement therapy in adults in relation to diagnostic criteria and different dosage algorithms

Phase 4

Completed

• Conditions: GH deficient adults; Metabolic and Endocrine -

• Registration Number: ACTRN12605000446662
• Lead Sponsor: St Vincent's Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-09-21
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

Adults with GH deficiency.

Exclusion Criteria

Significant pulmonary, cardiac, hepatic or renal disease or cancer.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in lean body mass[];GH-related adverse effects after 3 and 6 months growth hormone replacement[]

Secondary Outcome Measures

Name	Time	Method
IGF-1 levels[];Quality of life[];Whole body leucine turnover,[];Resting energy expenditure and fat oxidation[After 2 weeks and 12 weeks growth hormone replacement.]